General

New Mexico Application Registration Process

New Mexico Non-Resident/Fingerprint Card Scan Overview PowerPoint

Fingerprint background check services Frequently Asked Questions (FAQs)

Map of Fingerprint Location Sites

List of acceptable IDs needed for enrollment

Guidance on Multi-factor Authentication Applications

IDEMIA Background Check Result Access PowerPoint

Northwest Region Health Promotion Team

The CDC and FDA have streamlined COVID-19 vaccine recommendations, authorizing the use of bivalent COVID-19 vaccines for all recommended doses. In addition, previously unvaccinated individuals ages 6 and older are now recommended to receive one dose of a bivalent COVID-19 vaccine, and people ages 65 and older and those with immune compromise can receive a second bivalent vaccine. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.

COVID-19

COVID-19 Factsheet (English)
COVID-19 Factsheet (Spanish)

VFC Program Staff Listing

Health Council Priorities FY23 rev 3-17-23

The U.S. Drug Enforcement Agency (DEA) recently issued an alert regarding overdose deaths in the US linked to Xylazine, a non-opioid central nervous system depressant. It is used as a sedative, anesthetic, muscle relaxant, and analgesic in veterinary medicine and has not been approved for use in humans. Xylazine is usually mixed with other illicit drugs, like fentanyl, because it causes the effects of opioids to last longer. In New Mexico, six xylazine-involved deaths were reported in the last five years. Xylazine is an unscheduled drug that is easily accessed, so its presence in the illicit drug supply may increase over time, due to its low cost. Reports indicate that xylazine, alone or in combination with other drugs, is administered by injecting, snorting, swallowing, or inhaling it.

Stakeholder engagement and participation is critical, and required, to ensure we capture the information needed to make the best decisions for the Department of Health, Developmental Disabilities Supports Division service delivery system for the Developmental Disabilities (DD) Waiver, Mi Via (MV) Waiver and the Medically Fragile (MF) Waiver.

NM ACQ Subcommittee Initial PowerPoint

NM ACQ Mathematical Rate Study PowerPoint

For any question not answered here, please contact Public Consulting Group via email or phone at NMHCBSRateStudy@pcgus.com or (833) 528-1736.

Thank you again for participating in the ACQ Subcommittee Meeting that took place on January 10th. The Developmental Disabilities Supports Division (DDSD), who is working with Public Consulting Group LLC (PCG) heard valuable feedback which we used to improve the instructions and messaging of the rate study tools (the time study and cost report). Providers and vendors will receive instructions and invitations to training webinars this week.

The rate study is well underway for the Developmental Disabilities (DD), Mi Via (MV), and Medically Fragile (MF) Waiver services. Providers have received the cost report, and time study tools to prepare for completing them. These tools did not include Mi Via services, except for Consultant services. This is because in current policy, Mi Via rate ranges are based on what Medicaid currently pays for similar services under the Developmental Disabilities (DD) Waiver. Based on this policy, PCG’s recommended rate ranges for the Mi Via services in the scope of this rate study will be a range-based on the rate for the comparable DD Waiver services.

Rate Study Timelines